CTRI/2014/08/004840已完成3 期
A Comparative, Phase III, Multi-Center Study to Evaluate the Efficacy,Tolerability, and Safety of Azilsartan in Indian Adult Patients of Hypertension (AZILEHI Study)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 303
- 试验地点
- 5
- 主要终点
- Change from Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure
研究概览
简要总结
This study is an open label, randomized, multiple-dose, parallel study to evaluate the safety and efficacy of Azilsartan Test product (Hetero) and Reference product in mild to moderate essential hypertension. xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /
The primary objective is to study the efficacy of azilsartan in Indian adult patients of essential hypertension. The secondary objectives are to evaluate the tolerability and safety of azilsartan in Indian adult patients of essential hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Permuted block randomization, fixed
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •The patient willing to give written, signed, and dated informed consent to participate in the study before initiating any study related procedures 2.Patients with mild to moderate essential hypertension (defined as sitting trough clinic systolic blood pressure between 140 mmHg and 180 mmHg inclusive at Day minus 1 and 24-hour mean systolic blood pressure between 130 mmHg and 170 mmHg inclusive at Day 1).
- •Sitting trough clinic diastolic blood pressure <114mmHg at Day minus
- •3.Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from screening throughout the duration of the study 4.Clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator 5.Willing to discontinue current antihypertensive medications at the Screening Day minus 21 visit.
- •If the patient is on amlodipine prior to screening, the patient is willing to discontinue this medication at Screening Day minus 28.
排除标准
- •1.Required to take or continue taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication.
- •2.Hypersensitive to angiotensin II receptor blockers.
- •Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.
- •4.Recent history (within the last 6 months) of myocardial infarction, Patients with NYHA class III and IV heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack (Stable coronary artery disease (CAD) patients more than 3 months duration with or without angioplasty can be included).
- •5.Clinically significant cardiac conduction defects (e.g., 3rd degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation or flutter).
- •6.Hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
- •7.Secondary hypertension of any etiology.
- •8.Non-compliant with the study medication or any study related procedures 9.Severe renal dysfunction or disease (based on calculated creatinine clearance less than 30mL per min/1.73m2) at screening.
- •10.Known or suspected unilateral or bilateral renal artery stenosis.
- •11.History of drug or alcohol abuse within the past 2 years.
- •12.Previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.
- •(This criterion does not apply to those patients with basal cell or Stage 1 squamous cell carcinoma of the skin).
- •13.Hyperkalemia as defined by the central laboratory normal reference range at screening.
- •14.Upper arm circumference less than 24 cm or greater than 42 cm.
- •15.Alanine aminotransferase level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice at screening.
- •16.Currently is participating in another investigational study or has participated in an investigational study within 30 days prior to randomization.
- •17.Any other serious disease or condition at screening (or randomization) that would compromise patient safety, might affect life expectancy, or make it difficult to successfully manage and follow the patient according to the protocol.
- •18.Participated and treated in a previous study with azilsartan or a sartan, ACE inhibitors, and ANP & BNP inhibitors, within 30 days prior to randomization.
- •19.Patients with any other serious concurrent medical or surgical illness or malignancy 20.Patients with the current/past infections such as tuberculosis, herpes and/or patients with immune system disorders like HIV and SLE.
- •21.Any other disease state which could interfere with trial participation or trial evaluation as per investigator’s discretion 22.Women of child-bearing potential, pregnant or lactating women, women practicing contraception by other than barrier methods or intending to donate eggs within the projected duration of the study and post-study follow-up period 23.The physician is of the opinion that changing a patient’s trial medications would put the patient at risk.
结局指标
主要结局
Change from Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure
时间窗: Start to end of week 6 of study treatments
次要结局
- Change from Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
- Change from Baseline in the 24-hour Mean Systolic and Diastolic Blood Pressure measured by Ambulatory Blood Pressure Monitoring
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma SubjectsMultiple MyelomaNCT01091831Fondazione EMN Italy Onlus389
Unknown
不适用
An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated PneumoniaPneumoniaNCT01280461Taipei Medical University WanFang Hospital142
进行中（未招募）
3 期
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyProstate CancerNCT04181203UNICANCER490
终止
3 期
Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated PneumoniaVentilator-Associated Pneumonia (VAP)NCT01853982Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4
已完成
3 期
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast CancerHER2-positive Breast CancerNCT06107790Zhejiang Hisun Pharmaceutical Co. Ltd.570